medical centers during March 11, 2021–January 24, 2022. Using a case-control design, mRNA vaccine effectiveness (VE) against COVID-19–associated IMV and in-hospital death was evaluated among adults aged ≥18 years hospitalized at 21 U.S. However, how well mRNA vaccines protect against the most severe outcomes of these hospitalizations, including invasive mechanical ventilation (IMV) or death is uncertain. Patel, MD 1 IVY Network ( View author affiliations) View suggested citationĬOVID-19 mRNA vaccines (BNT162b2 and mRNA-1273 ) are effective at preventing COVID-19–associated hospitalization ( 1– 3). Hart, MA 2 Yuwei Zhu, MD 2 Katherine Adams, MPH 1 Diya Surie, MD 1 Meredith L. Stubblefield, MD 2 Adrienne Baughman 2 Kelsey N. Shapiro, MD 25 Natasha Halasa, MD 2 James D. Chang, MD, PhD 20 Christopher Mallow, MD 21 Carolina Rivas 21 Hilary M. Wilson, MD 19 Nida Qadir, MD 20 Steven Y. Busse, MD 17 Abhijit Duggal, MD 18 Jennifer G. Monto, MD 15 Akram Khan, MD 16 Catherine L. Johnson, MD 11 Vasisht Srinivasan, MD 11 Jay S. Gong, MD 10 Amira Mohamed, MD 10 Nicholas J. Hager, MD, PhD 8 Arber Shehu, MD 8 Matthew E. Mohr, MD 6 Anne Zepeski, PharmD 6 Tresa McNeal, MD 3 ,4 Shekhar Ghamande, MD 3 ,4 Kevin W. Self, MD 2 Manjusha Gaglani, MBBS 3 ,4 Adit A.
0 Comments
Leave a Reply. |